FIELD: medicine; experimental pathophysiology; endocrinology; cardiology; gastroenterology; oncology.
SUBSTANCE: invention can be used for effective correction of metabolic syndrome. For this purpose, Azilsartan is used at a dose of 1.5 mg/kg of animal body weight per day. Additionally, a non-alcoholic polyphenolic grape processing preparation, Fenokor, is used at a dose of 2 mg/kg of animal body weight per day, administered orally using a probe. The drugs are administered daily, starting from the 14th week of the fructose diet until the 24th week.
EFFECT: invention allows to effectively correct metabolic and inflammatory disorders that occur against the background of metabolic syndrome and other diseases accompanied by associated inflammation, with minimal side reactions.
1 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DIAGNOSING DEVELOPMENT OF INFLAMMATION DURING BACKGROUND OF METABOLIC SYNDROME IN EXPERIMENT | 2022 |
|
RU2813621C2 |
| METHOD FOR REHABILITATION OF PATIENTS WITH ISCHEMIC HEART DISEASE AT SANATORIUM-RESORT STAGE | 2021 |
|
RU2790237C1 |
| METHOD FOR PREVENTION OF POSTOPERATIVE COMPLICATIONS IN DENTAL PATIENTS WITH POST-COVID SYNDROME | 2023 |
|
RU2823132C1 |
| METHOD FOR CORRECTION OF METABOLIC DISORDERS AND SYSTEM OF ANTIOXIDANT PROTECTION IN METABOLIC SYNDROME WITH FATTY LIVER INVOLVEMENT | 2019 |
|
RU2701159C1 |
| DOCOSAHEXAENOIC ACID DERIVATIVES AND THEIR APPLICATION AS DRUGS | 2006 |
|
RU2441061C2 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME WITH VITAMIN D DEFICIENCY | 2018 |
|
RU2694842C1 |
| COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES | 2015 |
|
RU2664696C2 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
| COMPOSITION FOR METABOLIC SYNDROME CORRECTION | 2016 |
|
RU2616241C1 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF OBESITY AND ASSOCIATED METABOLIC DISORDERS | 2020 |
|
RU2763348C2 |
